Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye

by Pavlos Msaouel, Cheryl L. Walker, Giannicola Genovese, Nizar M. Tannir
Published 2020-09-01

Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values

by Jacob J. Adashek, Giannicola Genovese, Nizar M. Tannir, Pavlos Msaouel
Published 2020-01-01

The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma

by Andrew W. Hahn, Justin Lebenthal, Giannicola Genovese, Kanishka Sircar, Nizar M. Tannir, Pavlos Msaouel
Published 2022-01-01

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?

by Amishi Y. Shah, Jose A. Karam, Zita D. Lim, Chaan S. Ng, Nizar M. Tannir
Published 2015-03-01

Effect of scan duration on CT perfusion values in metastases from renal cell carcinoma

by Chaan S. Ng, Adam G. Chandler, Yanwen Chen, Wei Wei, Nizar M. Tannir, Brian P. Hobbs
Published 2023-06-01

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

by Jianjun Gao, Nizar M. Tannir, Padmanee Sharma, Mehmet Asim Bilen, Sumit K. Subudhi, Shi-Ming Tu
Published 2016-11-01

Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-An...

by Stepan M. Esagian, Ioannis A. Ziogas, Dimitrios Kosmidis, Mohammad D. Hossain, Nizar M. Tannir, Pavlos Msaouel
Published 2021-02-01

Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials

by Pavlos Msaouel, Nizar M. Tannir, Eric Jonasch, Hung Le, Andrew W Hahn, Omar Alhalabi, Erick Campbell
Published 2020-12-01

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions

by Jonathan Thouvenin, Nieves Martínez Chanzá, Omar Alhalabi, Hervé Lang, Nizar M. Tannir, Philippe Barthélémy, Gabriel G. Malouf
Published 2021-08-01

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma

by Chijioke Nze, Pavlos Msaouel, Mohamed H. Derbala, Bettzy Stephen, Abdulrahman Abonofal, Funda Meric-Bernstam, Nizar M. Tannir, Aung Naing
Published 2023-07-01

Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience

by Nidale Tarek, Rabih Said, Clark R. Andersen, Tina S. Suki, Jessica Foglesong, Cynthia E. Herzog, Nizar M. Tannir, Shreyaskumar Patel, Ravin Ratan, Joseph A. Ludwig, Najat C. Daw
Published 2020-10-01

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

by Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Published 2021-09-01

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

by Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Published 2021-08-01

Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma

by Ronan Flippot, Roger Mouawad, Jean-Philippe Spano, Morgan Rouprêt, Eva Compérat, Marc-Olivier Bitker, Jérôme Parra, Christophe Vaessen, Frederick Allanic, Quentin Manach, Nizar M. Tannir, David Khayat, Xiaoping Su, Gabriel G. Malouf
Published 2017-08-01

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

by Chung-Wei Lee, Thomas Powles, Sabina Signoretti, David F McDermott, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang
Published 2022-12-01

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

by Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel
Published 2021-04-01

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

by Mario Sznol, Adi Diab, Jonathan Zalevsky, Ute Hoch, Mehmet A Bilen, Giovanni Grignani, Nizar M Tannir, Erika Puente, Arjun V Balar, Daniel C Cho, Arlene O Siefker-Radtke, Lily Tang, David Chien, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Michael E Hurwitz
Published 2022-04-01

BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation

by Tianhong Pan, Song-Chang Lin, Kai-Jie Yu, Guoyu Yu, Jian H. Song, Valerae O. Lewis, Justin E. Bird, Bryan Moon, Patrick P. Lin, Nizar M. Tannir, Eric Jonasch, Christopher G Wood, Gary E. Gallick, Li-Yuan Yu-Lee, Sue-Hwa Lin, Robert L. Satcher
Published 2018-01-01

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma

by Xian-De Liu, Wen Kong, Christine B. Peterson, Daniel J. McGrail, Anh Hoang, Xuesong Zhang, Truong Lam, Patrick G. Pilie, Haifeng Zhu, Kathryn E. Beckermann, Scott M. Haake, Sevinj Isgandrova, Margarita Martinez-Moczygemba, Nidhi Sahni, Nizar M. Tannir, Shiaw-Yih Lin, W. Kimryn Rathmell, Eric Jonasch
Published 2020-05-01

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders

by A. Boilève, M. I. Carlo, P. Barthélémy, S. Oudard, D. Borchiellini, M. H. Voss, S. George, C. Chevreau, J. Landman-Parker, M-D Tabone, D. D. Chism, A. Amin, M. A. Bilen, D. Bosse, A. Coulomb-L’hermine, Xiaoping Su, T. K. Choueiri, Nizar M. Tannir, Gabriel G. Malouf
Published 2018-12-01